Search

Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin

메타 데이터

바이오화학분류
    • 바이오플라스틱
      1. 플라스틱
      2. 기타
    • 바이오정밀화학
      1. 화학제품
      2. 연료
      3. 기타
    • 화장품용 기능성소재
      1. 계면활성제⁄증점제
    • 의료용 화학소재
      1. 치료제
      2. 식품첨가제
논문

Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin

학술지

Biotechnology journal

저자명

Baik, Jong Youn; Dahodwala, Hussain; Oduah, Eziafa; Talman, Lee; Gemmill, Trent R.; Gasimli, Leyla; Datta, Payel; Yang, Bo; Li, Guoyun; Zhang, Fuming; Li, Lingyun; Linhardt, Robert J.; Campbell, Andrew M.; Gorfien, Stephen F.; Sharfstein, Susan T.

초록

<P>Heparin is the most widely used anticoagulant drug in the world today. Heparin is currently produced from animal tissues, primarily porcine intestines. A recent contamination crisis motivated development of a non-animal-derived source of this critical drug. We hypothesized that Chinese hamster ovary (CHO) cells could be metabolically engineered to produce a bioengineered heparin, equivalent to current pharmaceutical heparin. We previously engineered CHO-S cells to overexpress two exogenous enzymes from the heparin/heparan sulfate biosynthetic pathway, increasing the anticoagulant activity ???100-fold and the heparin/heparan sulfate yield ???10-fold. Here, we explored the effects of bioprocess parameters on the yield and anticoagulant activity of the bioengineered GAGs. Fed-batch shaker-flask studies using a proprietary, chemically-defined feed, resulted in ???two-fold increase in integrated viable cell density and a 70% increase in specific productivity, resulting in nearly three-fold increase in product titer. Transferring the process to a stirred-tank bioreactor increased the productivity further, yielding a final product concentration of ???90 관g/mL. Unfortunately, the product composition still differs from pharmaceutical heparin, suggesting that additional metabolic engineering will be required. However, these studies clearly demonstrate bioprocess optimization, in parallel with metabolic engineering refinements, will play a substantial role in developing a bioengineered heparin to replace the current animal-derived drug.</P>

발행연도

2015

발행기관

Wiley (John WileySons)

라이선스

cc-by-sa

ISSN

1860-6768

ISSN

1860-7314

10

7

페이지

pp.1067-1081

0건의 논문이 있습니다.

0건의 특허가 있습니다.

0건의 무역이 있습니다.

3건의 후보군 물질이 있습니다.

2 2023-12-11
3 2023-12-11

논문; 2015-06-24

Export

About

Search

Trend